A Delphi consensus on clinical features, diagnosis and treatment of major depressive disorder patients with anhedonia amongst psychiatrists in the Asia-Pacific.

"Conflict of interest CN reports consultancy for Janssen-Cilag, Lundbeck, Grunbiotics, Servier and Eli Lilly, and speaker honoraria from Servier, Lundbeck, Eli Lilly, Janssen-Cilag, Astra-Zeneca, and Pfizer in the last 10 years, unrelated to this work. TK reports personal fees from Janssen Asia Pacific related to the submitted work. TK also reports grants and personal fees from Sumitomo Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Shionogi & Co., Ltd., Takeda Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., and Eisai Co., Ltd., personal fees from Taisho Pharma Co., Ltd., Mochida Pharmaceutical Co., Janssen Pharmaceutical K.K., Janssen Asia Pacific, Yoshitomiyakuhin, MSD K.K., Kyowa Pharmaceutical Industry Co., Ltd., Taisho Pharmaceutical Co., Ltd., Teijin Pharma, Viatris, Mylan N.V., Lundbeck Japan K.K., EA Pharma Co., Ltd., Nihon Medi-physics Co., Ltd., Ono Pharmaceutical Co., Ltd., outside the submitted work. YY reports serving on the advisory board for Janssen-Cilag, Pfizer, Eli Lilly and Lundbeck, and reports grants from GlaxoSmithKline, Eli Lilly, Pfizer, Janssen-Cilag, Sanofi-Aventis, Wyeth, Otsuka, Astellas, Dai Nippon Sumitomo, Lundbeck, Roche, Mitsubishi Tanabe and Boehringer Ingelheim. KH is an employee of Janssen Pharmaceutical Companies of Johnson & Johnson, Asia Pacific. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

"The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The modified Delphi panel study was funded by Janssen Asia Pacific. Janssen Asia Pacific was not involved in conducting the study and did not influence the decisions or outcomes of the consensus."